<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433508</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-cirrhosis-01</org_study_id>
    <nct_id>NCT03433508</nct_id>
  </id_info>
  <brief_title>Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock</brief_title>
  <official_title>Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock: An Open Label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consecutive cirrhotics who present to emergency department of ILBS with documented or
      suspected sepsis induced hypotension with Hb &lt;8 gm/dl will be randomly assigned to
      restrictive (Target Hb 7-8 gm/dl) to liberal (Target Hb 10-11 gm/dl) group in a 1:1
      proportion At admission, all patients will undergo physical examination and baseline
      investigations to identify site of sepsis. Enrolled patients will be given PRBC-transfusion
      (Not more than two units of PRBC/day) when they reach their assigned trigger value (Hb 7-8
      g/dl or 10-11 g/dl ) during the entire ICU stay. All other interventions will be at the
      discretion of clinicians.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality in both groups</measure>
    <time_frame>28 dyas</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in vasopressors in both groups</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement is defined as tapering the dose of vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications in both groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU (Intensive Care Unit) stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of mechanical ventilation in both groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Liberal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To maintain the target Hemoglobin of 7 to 8 gm/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liberal</intervention_name>
    <description>2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days</description>
    <arm_group_label>Liberal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive</intervention_name>
    <description>To maintain the target Hemoglobin of 7 to 8 gm/dL.</description>
    <arm_group_label>Restrictive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhosis with septic shock.

          2. Age &gt;18 years

        Exclusion Criteria:

          1. Previous severe adverse reaction with blood products,

          2. Disseminated intravascular coagulopathy

          3. HCC

          4. Pregnancy

          5. Malignancy

          6. Active gastrointestinal bleeding

          7. Intracranial bleeding

          8. Chronic Kidney disease with Maintenance Hemodialysis

          9. Pulmonary Edema

         10. Congestive Heart Failure

         11. Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Harsh Tevathia, MD</last_name>
    <phone>01146300000</phone>
    <email>hershey4686@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harsh Tevethia, MD</last_name>
      <phone>7835056137</phone>
      <email>hershey4686@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

